Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

AbbVie CEO Gonzalez defends Allergan takeover

AbbVie CEO Gonzalez defends Allergan takeover In light of the regulatory difficulties experienced by Bristol-Myers Squibb in its proposed $73bn takeover of Celgene, AbbVie was quizzed about any potential issues that might emerge from the Federal

Liver cancer failure dents Opdivo potential by $1bn, says analyst

Liver cancer failure dents Opdivo potential by $1bn, says analyst Adds to bad news of forced Otezla sell-off. It’s been a tough start to the week for Bristol-Myers Squibb, with two events carving billions of dollars from group

Faced with regulator’s merger concerns, BMS want to offload Otezla

Faced with regulator’s merger concerns, BMS want to offload Otezla Sell-off will mean merger delay. Bristol-Myers Squibb has announced plans to sell off its blockbuster psoriasis drug Otezla in order to gain regulatory approval for its $74bn acquisition of ... The company said in a statement: “Bristol-Myers Squibb

Merck says it has plenty in the pipe beyond Keytruda

Merck says it has plenty in the pipe beyond Keytruda That’s a big contrast to its rival Bristol-Myers Squibb, whose checkpoint inhibitor Opdivo (nivolumab) is locked in a market battle with Keytruda that Merck’s drug is currently winning,

Celgene says no to Mereo’s cancer drug etigilimab

Celgene says no to Mereo’s cancer drug etigilimab Bristol-Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics